Business Context and Reporting Period
Nanoviricides, Inc. filed this Form 8-K on October 17, 2011, to disclose a material event under Item 7.01 (Regulation FD Disclosure). The company is incorporated in Nevada and maintains its principal executive offices in West Haven, Connecticut.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate governance event regarding insider trading plans.
Material Changes
The primary event reported is the termination of a Rule 10b5-1 trading plan by Dr. Anil Diwan, the Company's President and Chairman. Key details include:
- Plan Termination: Dr. Diwan terminated his trading plan with Laidlaw & Co. (UK) Ltd. on October 17, 2011.
- Authorized Volume: The plan originally authorized the sale of up to 2,000,000 shares of common stock.
- Executed Volume: Between May 6, 2011, and October 17, 2011, Dr. Diwan sold an aggregate of 1,173,655 shares under the plan.
- Remaining Authorization: Approximately 826,345 shares remained unsold at the time of termination.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The disclosure is strictly factual regarding the cessation of the pre-arranged trading plan.
Investor Verification Checklist
- Verify the current share ownership of Dr. Anil Diwan following the sale of 1,173,655 shares.
- Confirm whether the termination of the trading plan impacts future insider selling activity or market perception.
- Review recent 10-Q or 10-K filings for the company's actual financial performance, as this 8-K provides no financial metrics.